MGTX vs. PTGX, CNTA, MESO, CGON, AGIO, HRMY, IDYA, BLTE, JANX, and GLPG
Should you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Protagonist Therapeutics (PTGX), Centessa Pharmaceuticals (CNTA), Mesoblast (MESO), CG Oncology (CGON), Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Janux Therapeutics (JANX), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry.
MeiraGTx vs.
Protagonist Therapeutics (NASDAQ:PTGX) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
In the previous week, Protagonist Therapeutics had 16 more articles in the media than MeiraGTx. MarketBeat recorded 18 mentions for Protagonist Therapeutics and 2 mentions for MeiraGTx. Protagonist Therapeutics' average media sentiment score of 0.68 beat MeiraGTx's score of 0.50 indicating that Protagonist Therapeutics is being referred to more favorably in the media.
98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 5.4% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 8.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Protagonist Therapeutics has a net margin of 52.76% compared to MeiraGTx's net margin of -633.05%. Protagonist Therapeutics' return on equity of 34.68% beat MeiraGTx's return on equity.
Protagonist Therapeutics has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Protagonist Therapeutics currently has a consensus price target of $55.44, suggesting a potential upside of 42.84%. MeiraGTx has a consensus price target of $23.50, suggesting a potential upside of 245.28%. Given MeiraGTx's higher possible upside, analysts plainly believe MeiraGTx is more favorable than Protagonist Therapeutics.
Protagonist Therapeutics has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Protagonist Therapeutics received 92 more outperform votes than MeiraGTx when rated by MarketBeat users. However, 71.64% of users gave MeiraGTx an outperform vote while only 61.21% of users gave Protagonist Therapeutics an outperform vote.
Summary
Protagonist Therapeutics beats MeiraGTx on 14 of the 18 factors compared between the two stocks.
Get MeiraGTx News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MeiraGTx Competitors List
Related Companies and Tools
This page (NASDAQ:MGTX) was last updated on 3/3/2025 by MarketBeat.com Staff
Free MGTX Stock Alerts